APOE Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer
Wanderley, C. W. S.; Michaud, D. E.; Shimada, K.; Nelson, A.; Fu, J.; Schnitt, S. J.; Tolaney, S. M.; Mittendorf, E. A.; Barroso-Sousa, R.; Waks, A.; Tarantino, P.; Guerriero, J. L.
Show abstract
Novel anti-HER2 antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan (T-DXd), have shown efficacy in tumors with varying HER2 expression, including HER2-low and even tumors with minimal HER2 presence. This has sparked interest in the biology underlying the HER2 expression spectrum. Using molecular and multiplexed imaging, we revealed distinct immune and stromal features in treatment-naive, hormone receptor-positive (HR+) HER2-low versus HER2-0 tumors. HER2-0 tumors exhibit inflammatory and tissue remodeling gene signatures, with enrichment of APOE tumor-associated macrophages (TAMs) and DOCK4 CD4 T cells. In contrast, HER2-low tumors are more immunosuppressed, with elevated cell cycle, metabolic, and estrogen signaling pathways, suggesting increased proliferative activity. These findings underscore key biological differences between HR+ HER2-low and HER2-0 breast cancers, and may inform more tailored therapeutic strategies. Statement of significanceThis study revealed the distinct biological profiles of HR+ HER2-low and HER2-0 breast tumors. HER2-0 tumors exhibit inflammatory and tissue remodeling signatures, whereas HER2-low tumors have elevated cell cycle, metabolic, and estrogen signaling. These insights may help refine therapeutic approaches to improve outcomes for breast cancer patients.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits 96%
- Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas 95%
- Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response 95%
Similar papers in this journal
Similar papers in this journal
- Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBC 97%
- Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug Conjugates 96%
- Breast Cancer Remodels Lymphatics in Sentinel Lymph Nodes 95%
Similar papers in this journal
- The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer 96%
- The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ 95%
- Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors 94%
Similar papers in this journal
- Mapping the breast tumor microenvironment: proximity analysis reveals spatial relationships between macrophage subtypes and metastasis-initiating cancer cells 97%
- A SNAI2-PEAK1 stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting a cytokine expression profile that converges on PI3K/Akt signaling 95%
- Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.